Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B

S. Yuki, K. Shinozaki, T. Kashiwada, T. Kusumoto, M. Iwatsuki, H. Satake, S. Tokunaga, Y. Emi, A. Makiyama, Y. Kawamoto, Y. Komatsu, M. Shimokawa, H. Saeki, E. Oki, H. Baba, Y. Maehara

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)viii225
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - Oct 1 2018

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Yuki, S., Shinozaki, K., Kashiwada, T., Kusumoto, T., Iwatsuki, M., Satake, H., Tokunaga, S., Emi, Y., Makiyama, A., Kawamoto, Y., Komatsu, Y., Shimokawa, M., Saeki, H., Oki, E., Baba, H., & Maehara, Y. (2018). Updated analysis of a phase II study of SOX plus trastuzumab for the patients with HER2 positive advanced or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS1501B. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii225. https://doi.org/10.1093/annonc/mdy282.052